The acute ischemic stroke therapeutics global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Acute Ischemic Stroke Therapeutics Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The acute ischemic stroke therapeutics market size has grown strongly in recent years. It will grow from $8.47 billion in 2023 to $9.24 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to an increase in the number of patients, a rise in the geriatric population, a growing prevalence of obesity, a rising prevalence of ischemic stroke, and rising hypertension.
The acute ischemic stroke therapeutics market size is expected to see strong growth in the next few years. It will grow to $13.17 billion in 2028 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to increasing preference for online pharmacies, increasing cardiovascular diseases, increasing cholesterol levels, rising prevalence of diseases, and rising prevalence of ischemic stroke. Major trends in the forecast period include advancements in medical technology, the integration of artificial intelligence, the integration of machine learning, advancements in neurology, and the adoption of technologically advanced diagnostics.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-therapeutics-global-market-report
Scope Of Acute Ischemic Stroke Therapeutics Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Acute Ischemic Stroke Therapeutics Market Overview
Market Drivers –
The rising prevalence of hypertension is expected to propel the growth of the acute ischemic stroke therapeutics market going forward. Hypertension, or high blood pressure, is a medical condition where the force of blood against the walls of the arteries is consistently elevated, increasing the risk of heart disease, stroke, and other health problems. The prevalence of hypertension is primarily driven by an aging population and increased rates of obesity. Acute ischemic stroke therapeutics help manage rising hypertension by addressing stroke-induced complications and preventing further cerebrovascular damage, which is often linked to high blood pressure. For instance, in May 2023, according to the National Health Service England, a UK-based government department, around 30% of adults in the US had hypertension, with 15% having untreated hypertension. Further, the prevalence of hypertension increased with age, ranging from 9% in adults aged 16 to 44 to 60% in those aged 65 and over. Therefore, the rising prevalence of hypertension drives the growth of the acute ischemic stroke therapeutics market.
Market Trends –
Major companies operating in the acute ischemic stroke therapeutics market are focusing on advancing medical technologies through innovative solutions, such as exosome-based therapy for a neurological indication, to enhance the effectiveness of treatment and improve patient outcomes. Exosome-based therapy is an emerging and innovative approach to treating acute ischemic stroke, focusing on using exosomes, small extracellular vesicles (30-150 nm in diameter) that are naturally released by cells and play a role in cell-to-cell communication. For instance, in January 2024, Aruna Bio, a US-based developer of neural exosome platforms, received the Food and Drug Administration (FDA) clearance for its investigational new drug application for AB126, the first exosome-based therapy to enter human clinical trials targeting a neurological indication, specifically acute ischemic stroke. A Phase 1b/2a clinical trial is set to begin in early 2024, focusing on the safety, tolerability, and preliminary efficacy of AB126 in patients post-thrombectomy with poor prognosis. Derived from proprietary neural stem cells, AB126 can cross the blood-brain barrier and has shown anti-inflammatory and neuroprotective effects in preclinical studies.
The acute ischemic stroke therapeutics market covered in this report is segmented –
1) By Type: Thrombolytic Therapeutics, Antihypertensive Therapeutics, Antiplatelet Therapeutics, Anticoagulants
2) By Route Of Administration: Oral, Parenteral
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Hospitals, Ambulatory Surgical Center, Diagnostic Centers
Get an inside scoop of the acute ischemic stroke therapeutics market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=19265&type=smp
Regional Insights –
North America was the largest region in the acute ischemic stroke therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute ischemic stroke therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies operating in the acute ischemic stroke therapeutics market are Johnson & Johnson, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Medtronic plc, Eli Lilly and Company, Amgen Inc., Stryker Corporation, Teva Pharmaceutical Industries Limited, Merck & Co. Inc., Otsuka Pharmaceutical Co. Ltd., Biogen Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Genentech Inc., NoNO Inc., Athersys Inc., XBiotech Inc., ZZ Biotech LLC
Table of Contents
1. Executive Summary
2. Acute Ischemic Stroke Therapeutics Market Report Structure
3. Acute Ischemic Stroke Therapeutics Market Trends And Strategies
4. Acute Ischemic Stroke Therapeutics Market – Macro Economic Scenario
5. Global Acute Ischemic Stroke Therapeutics Market Size and Growth
.
.
.
32. Global Acute Ischemic Stroke Therapeutics Market Competitive Benchmarking
33. Global Acute Ischemic Stroke Therapeutics Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Acute Ischemic Stroke Therapeutics Market
35. Acute Ischemic Stroke Therapeutics Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
